Total Funding
35
35
Total FundingPost-IPO Equity raised
Growth Score
-1 pts
Heat Score
-5 pts
Company Performance Metrics
Score
Trend
AI Content may contain mistakes and is not legal, financial or investment advice.Learn more.
Growth Score - The measure of growth based on company activity, operational metrics, and investments
Growth Trend - The change in the growth score over the given time period
Heat Score - The measure of the market interest, media activity, and Crunchbase profile activity
Heat Trend - The change in the heat score over the given time period
See more interactive data and historical milestones on desktop for the best experience
140692
ESSA Pharma is a biotechnology company that develops new drugs for prostate cancer.
Acquired by 
XenoTherapeutics
David Parkinson: President & CEOPast Role: Nodality, President & CEO
Paul Cossum: Executive Vice President of Research & DevelopmentPast Role: Aronex Pharmaceuticals, Vice President of Preclinical Development
About the Company
ESSA is a pharmaceutical company focused on the development of small molecule drugs for the treatment of cancer, with a focus on advanced prostate cancer. ESSA is developing drugs that selectively block the N-terminal domain of the androgen receptor (AR). The AR is required for the growth and survival of most prostate cancer; therefore, the AR
N-terminal domain is an ideal target for next-generation hormone therapy.
